Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration

Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration

Abstract:

Nanoscopic structures are small vehicles for delivery of vaccines or drugs that are measured in nanometers and best visualized by electron microscopy. An example of the first approved human nanoscopic vaccine was Dr. Jonas Salk’s formalin inactivated polio vaccine. The inactivated polio vaccine is approved currently for Intramuscular and subcutaneous administration. It is used in several countries like India as a three dose intradermal priming vaccination before administration of multiple doses of the attenuated oral polio vaccine (Sabin vaccine). 

Two examples of nanoscopic vaccines using our SubATVax™ technology are our SARS-COV-2 vaccine (USPTO# 11,911,461 B1 “Adjuvanted vaccines containing modified S1 spike protein of SARS-COV-2 variant C.1.2 for subcutaneous administration and methods of use”) and an interesting nanoscopic Influenza vaccine, using an FDA approved antigen preparation from another vaccine company, mixed with preformed SubATVax™ nonphospholipid liposomes. How these adjuvanted vaccines are prepared and electron micrographic studies of nanoscopic vaccines will be reviewed.

Biography:

Dr. Wright completed an undergraduate degree in Biology from the University of Virginia in 1972, his M.D. degree from the University of Virginia in 1976, an internship in internal medicine at Columbia P&S Harlem Hospital in New York City in 1977. He then spent 3 years in the Army in Germany seeing patients before returning to the United States to complete a two residency in Internal Medicine, a 3 year research fellowship in Infectious Disease both at Walter Reed Army Medical Center in Washington D.C and tropical medicine training at Walter Reed Army Institute of Research. During his fellowship he set-up the first HIV-1 clinic in the military which he continued to run until 1988. He then left to cofound Univax Biologics, the third biotechnology company in Maryland. In 1993 he cofounded Novavax.  Dr. Wight left Novavax in 2006. He has set-up 3 additional companies LPJP, Inc., David Craig Wright, M.D. Inc. (both California S corporations) and D4 Labs, LLC (California LLC). Dr. Wright has authored or co-authored over 20 issued US patents since 1989.